UNSPSC 51142029: Phenicarbazide

This classification denotes an analgesic and antipyretic with the molecular formula C7H9N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1LR2578324, chemically known as 2-phenylhydrazide, carbamic acid but generally known as phenicarbazide, which bears US NIH Compound Identifier 61002. European Medicines Agency schedules Phenicarbazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09763MIG. The term PHENICARBAZIDE is an International Non-Proprietary Name.

UNSPSC 51142029 Phenicarbazide is a Commodity code that in recent state and local solicitations captures a broader set of pharmaceutical procurement activities—primarily generic pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems—rather than the narrow chemical compound the code name suggests. State and local governments buying under this code are acquiring finished pharmaceutical products and health-related supplies for community health programs, pharmacy benefit management, and public-health initiatives. Issuing bodies span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, for example, solicited naloxone and drug deactivation systems for community health delivery; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer pharmacy programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration's Office of State Procurement pursued generic pharmaceuticals and OTC products for participating state and local facilities across multiple jurisdictions including Oregon.

Recent activity concentrates in Florida, Texas, and Minnesota. The Seminole County procurement (IFB 60459723LAS, posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida; vendors must include shipping costs and comply with E-Verify, workers' compensation insurance, and drug-free workplace certification, with a two-year initial term and one-year renewal option. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The MMCAP RFP (S1070000015802, posted January 20, 2026, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with awards effective July 1, 2026; vendors must maintain cGMP and Drug Supply Chain Security Act compliance, hold $5 million commercial general liability and $2 million professional liability coverage, and accept a 3 percent administrative fee on purchases.